Mantle Cell Lymphoma
Conference Coverage
ASH 2022: New clinical data challenge long-held assumptions
Fresh research to be unveiled at the 2022 American Society of Hematology conference seems to overturn conventional wisdom across a range of issues...
News
High cost and demand for old cancer drug sparks crisis
Experts have voiced alarm at the scarcity and cost of fludarabine, an old drug deemed crucial to cellular therapy for leukemia.
News
Transplant provides no clear survival benefit in real-world MCL study
The findings apparently contradict the survival benefit seen in clinical trial data, authors said, but are consistent with other recent...
News
Blame MCL, not transplantation, for late effects?
In patients with mantle cell lymphoma, long-term complications appeared to be caused by the disease itself, not by intensive therapy.
News
Phase 3 trial yields better way to predict MCL outcomes
In a phase 3 trial of mantle cell lymphoma outcomes, repeated evaluations of minimal residual disease over time improved prognostic power.
News
Gloom lifting as MCL treatments evolve
A rare blood cancer remains incurable, yet new therapies have yielded improved prognoses and survival rates.
News
FDA approved acalabrutinib tablet for MCL, CLL, SLL
Acalabrutinib (Calquence) in tablet formulation approved by FDA.
News
‘Plethora’ of new MCL treatment options
New and potential treatments have emerged for relapsed/refractory mantle cell lymphoma (R/RMCL), a rare but steadily increasing form of non-...
News
Noted oncologist ponders death, life, care inequities
A photojournalist-turned-physician practiced in India and the United Kingdom before rising to prominence in U.S. community oncology.
News
First drug therapy approved for childhood GVHD
FDA greenlights ibrutinib for child blood cancer patients with chronic graft-versus-host disease.